Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Endo International (ENDP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Endo (ENDP)

by Zacks Equity Research

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Is Endo (ENDP) Down 33% Since Last Earnings Report?

by Zacks Equity Research

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.

Mallinckrodt Up on New York's Support for Opioid Settlement

by Zacks Equity Research

Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.

Implied Volatility Surging for Endo International (ENDP) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4

by Zacks Equity Research

Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.

Endo International (ENDP) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 29.82% and 5.25%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

by Sweta Killa

The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.

Here's Why You Should Add BioDelivery Stock to Your Portfolio

by Zacks Equity Research

Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.

J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

by Zacks Equity Research

A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

by Zacks Equity Research

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

Indrajit Bandyopadhyay headshot

Will J&J be Able to Overcome Its Legal Troubles in 2020?

by Indrajit Bandyopadhyay

Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

Implied Volatility Surging for Endo (ENDP) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

Why Is Endo (ENDP) Up 12.3% Since Last Earnings Report?

by Zacks Equity Research

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Options Traders Expect Huge Moves in Endo (ENDP) Stock

by Zacks Equity Research

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

by Zacks Equity Research

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

BioDelivery's Belbuca Sales & Symproic Addition Encouraging

by Zacks Equity Research

BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.

Kinjel Shah headshot

Fed Reportedly Opens Criminal Investigation on Opioid Makers

by Kinjel Shah

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

by Zacks Equity Research

The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

Company News For Nov 21, 2019

by Zacks Equity Research

Companies in the news are: URBN, KNSA, ACB, ENDP

Madhu Goel headshot

BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View

by Madhu Goel

BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.

Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.

Endo International (ENDP) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 13.21% and 3.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Endo International (ENDP) Q3 Earnings Expected to Decline

by Zacks Equity Research

Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.